4.8 Article

OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 130, Issue 7, Pages 3528-3542

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI131992

Keywords

-

Funding

  1. Maria Montano Facility Cancer Center Support Grant [NCI CA060553]
  2. NIH [1S10OD011996-01, U54CA199091, R01CA208354, R01CA222963]
  3. Riviera Foundation United-4-a-Cure Award
  4. Flow Cytometry Core Facility Cancer Center Support Grant [NCI CA060553]

Ask authors/readers for more resources

Plasmacytoid DCs (pDCs), the major producers of type I interferon, are principally recognized as key mediators of antiviral immunity. However, their role in tumor immunity is less clear. Depending on the context, pDCs can promote or suppress antitumor immune responses. In this study, we identified a naturally occurring pDC subset expressing high levels of OX40 (OX40(+) pDC) enriched in the tumor microenvironment (TME) of head and neck squamous cell carcinoma. OX40(+) pDCs were distinguished by a distinct immunostimulatory phenotype, cytolytic function, and ability to synergize with conventional DCs (cDCs) in generating potent tumor antigen-specific CD8(+) T cell responses. Transcriptomically, we found that they selectively utilized EIF2 signaling and oxidative phosphorylation pathways. Moreover, depletion of pDCs in the murine OX40(+) pDC-rich tumor model accelerated tumor growth. Collectively, we present evidence of a pDC subset in the TME that favors antitumor immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available